Biocon cancels plans to market Novo Nordisk generics in China due to local competition, focusing on other markets.

Biotechnology firm Biocon Ltd on Thursday said its board has approved the acquisition of optionally convertible debentures of ...

Indian drugmaker Biocon has abandoned plans to market generic versions of Novo Nordisk’s hot-selling diabetes and weight-loss drugs in China due to local competition, a senior executive said.

The shares of Biocon, PB Fintech and GMR Airports are expected to be in focus on May 27, 2025, Friday. Biocon will acquire ...

HCL Technologies Ltd., L&T Finance Ltd., the New India Assurance Co., Biocon Ltd. and Kaynes Technology India Ltd. are some ...

Biocon Ltd acquires Biocon Biologics debentures from Goldman Sachs for USD 198.5 million. The acquisition involves 1,125 ...

Biotechnology firm Biocon Ltd announces its board's approval to acquire optionally convertible debentures of its subsidiary ...

The Subject Expert Committee (SEC) on Oncology and Hematology, functioning under the Central Drugs Standard Control ...

With the stock currently priced at Rs 350.85, Biocon's recent financial performance, high trading volume, and presence in major market indices collectively indicate sustained investor interest and ...